(Q45374783)

13 December 2017

title

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation (English)

1 reference

13 December 2017

6

Jan Wilschut

1 reference

13 December 2017

3

Tjarko Meijerhof

1 reference

13 December 2017

Toon Stegmann

1

1 reference

13 December 2017

Tobias Kamphuis

series ordinal

2

1 reference

13 December 2017

Ellen Goud

series ordinal

4

1 reference

13 December 2017

Aalzen de Haan

series ordinal

5

1 reference

13 December 2017

language of work or name

English

0 references

publication date

25 June 2010

1 reference

13 December 2017

1 reference

13 December 2017

volume

28

1 reference

13 December 2017

issue

34

1 reference

13 December 2017

page(s)

5543-5550

1 reference

Immunopathology of RSV infection: prospects for developing vaccines without this complication

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Respiratory syncytial virus infection in elderly and high-risk adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

The virosome concept for influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal®)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Virosomes for antigen and DNA delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Bacterial cell wall components as immunomodulators--I. Lipopeptides as adjuvants for parenteral and oral immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

A rapid and sensitive sub-micro phosphorus determination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Sendai virosomes revisited: reconstitution with exogenous lipids leads to potent vehicles for gene transfer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Short-chain phosphatidylcholines as superior detergents in solubilizing membrane proteins and preserving biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Preservation of the native structure and function of Ca2+-ATPase from sarcoplasmic reticulum: solubilization and reconstitution by new short-chain phospholipid detergent 1,2-diheptanoyl-sn-phosphatidylcholine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

inferred from DOI database lookup

7 January 2021

based on heuristic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.041

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.06.041

1 reference

13 December 2017

1 reference